Cheetah Medical Set To Compete In Fast-Growing Hemodynamic Monitoring Market
This article was originally published in Start Up
In February, Cheetah Medical Inc. raised $9 million in a late financing round to support commercialization of its noninvasive, continuous hemodynamic monitoring system. It’s a product sector that’s received lots of attention recently.
You may also be interested in...
Edwards Lifesciences announced that it was acquiring private Dutch company BMEYE BV, the developer of a new noninvasive technology for hemodynamic monitoring. Noninvasive hemodynamic monitoring has long been “The Holy Grail” in critical care, and non-invasive technology opens up new applications and new markets for Edwards as well.
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker